Intellia Therapeutics, Inc.
Every calculator, already run for NTLA
Open the full toolkit →You have the numbers on NTLA. Get the argument.
A written report on which of these readings actually decide the outcome for Intellia Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering NTLAAnalyst Price Target Disagreement for Intellia Therapeutics, Inc.
Wall Street's bull case implies +402% from the current price; the bear case implies -34%. A 437% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for NTLA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimm…
NTLA — frequently asked
Is NTLA a buy right now?
Wall Street's consensus rating on Intellia Therapeutics, Inc. is Buy across 19 analysts, with a mean price target of $24.00 (+98% vs. the current $12.14). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is NTLA's next earnings date?
Intellia Therapeutics, Inc. is next scheduled to report earnings around Nov 5, 2026. A full NTLA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Intellia Therapeutics, Inc.?
Analysts covering Intellia Therapeutics, Inc. (NTLA) range from a bear-case target of $8.00 to a bull-case high of $61.00, with a mean consensus target of $24.00 across 17 analysts. The spread of $53.00 (437% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Intellia Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Intellia Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NTLA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Intellia Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.